Mut Y human homologue-associated polyposis is a recently described colorectal adenomatous polyposis with an autosomal recessive mode of inheritance. Several extracolonic manifestations have been reported in patients affected by Mut Y human homologue-associated polyposis (MAP). Among these, duodenal polyposis, a highly prevalent manifestation of Adenomatous Polyposis Coli related familial adenomatous polypyposis, is undoubtedly part of the clinical spectrum of the disease. The true association of other clinical manifestations with MAP remains questionable.We report the observation of two patients affected by MAP who developed an adenocarcinoma of the duodenum in the context of duodenal polyposis. These observations emphasize the malignant potential of MAP-associated duodenal polyposis and the need to enroll these patients into an upper gastrointestinal surveillance programme. Moreover, one of our patients was also diagnosed with a scapular chondrosarcoma, the other one with a high-grade astrocytoma. Although these tumours may be coincidental, we cannot rule out a real albeit rare association with MAP.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MEG.0b013e3282f5f749 | DOI Listing |
Thorac Cancer
January 2025
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: The clinical implications of different EML4-ALK fusion variants remain poorly elucidated in the era of second-generation ALK inhibitors.
Methods: This was a retrospective cohort study, wherein patients diagnosed with locally advanced or metastatic non-small cell lung cancer harboring EML4-ALK fusion were stratified into two cohorts based on their first-line treatment: Cohort 1 received alectinib, while Cohort 2 received crizotinib. Statistical analysis was employed to investigate the impact of different EML4-ALK variants and TP53 status on the efficacy of first-line ALK-TKIs.
Magn Reson Med
January 2025
Department of Radiology, Johns Hopkins University, Baltimore, Maryland, USA.
Purpose: To develop and evaluate a physics-driven, saturation contrast-aware, deep-learning-based framework for motion artifact correction in CEST MRI.
Methods: A neural network was designed to correct motion artifacts directly from a Z-spectrum frequency (Ω) domain rather than an image spatial domain. Motion artifacts were simulated by modeling 3D rigid-body motion and readout-related motion during k-space sampling.
Nat Commun
January 2025
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Glioma is a highly fatal and heterogeneous brain tumor with few known risk factors. Our study examines genetically predicted variability in blood cell indices in relation to glioma risk and survival in 3418 cases and 8156 controls. We find that increased platelet to lymphocyte ratio (PLR) confers an increased risk of glioma (odds ratio (OR) = 1.
View Article and Find Full Text PDFCommun Biol
January 2025
Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, USA.
Pseudouridine (Ψ) is an abundant RNA chemical modification that plays critical biological functions. Current Ψ detection methods are limited in identifying Ψs at base-resolution in U-rich sequence contexts, where Ψ occurs frequently. Here we report "Mut-Ψ-seq" that utilizes the classic N-cyclohexyl N'-(2-morpholinoethyl)carbodiimide (CMC) agent and an evolved reverse transcriptase ("RT-1306") for Ψ mapping at base-resolution.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
January 2025
Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Malignant gliomas are heterogeneous tumors, mostly incurable, arising in the central nervous system (CNS) driven by genetic, epigenetic, and metabolic aberrations. Mutations in isocitrate dehydrogenase (IDH1/2) enzymes are predominantly found in low-grade gliomas and secondary high-grade gliomas, with IDH1 mutations being more prevalent. Mutant-IDH1/2 confers a gain-of-function activity that favors the conversion of a-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), resulting in an aberrant hypermethylation phenotype.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!